;PMID: 8759031
;source_file_854.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..154] = [t:50..154]
;2)sentence:[e:155..249] = [t:155..249]
;3)section:[e:253..354] = [t:253..354]
;4)section:[e:358..506] = [t:358..506]
;5)sentence:[e:510..701] = [t:510..701]
;6)sentence:[e:702..1030] = [t:702..1030]
;7)sentence:[e:1031..1235] = [t:1031..1235]
;8)sentence:[e:1236..1491] = [t:1236..1491]
;9)sentence:[e:1492..1658] = [t:1492..1658]
;10)sentence:[e:1659..1792] = [t:1659..1792]
;11)sentence:[e:1793..1993] = [t:1793..1993]
;12)sentence:[e:1994..2211] = [t:1994..2211]
;13)section:[e:2215..2259] = [t:2215..2259]

;section 0 Span:0..44
;Biochem Pharmacol. 1996 Aug 23;52(4):587-95.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (RB:[17..18] .)
        (CD:[19..23] 1996) (IN:[24..27] Aug) (CD:[28..34] 23;52-LRB-)
        (CD:[34..36] 4-RRB-) (CD:[36..40] :587) (::[40..41] -) (CD:[41..43] 95)
        (.:[43..44] .)))

;sentence 1 Span:50..154
;Atypical cytochrome P450 induction profiles in glomerular mesangial cells at
;the  mRNA and enzyme level.
;[59..74]:cyp450:"cytochrome P450"
;[132..136]:substance:"mRNA"
;[141..147]:substance:"enzyme"
(SENT
  (NP-HLN
    (NP (JJ:[50..58] Atypical)
      (NML (NN:[59..69] cytochrome) (NN:[70..74] P450))
      (NN:[75..84] induction) (NNS:[85..93] profiles))
    (PP-LOC (IN:[94..96] in)
      (NP
        (NP (JJ:[97..107] glomerular) (JJ:[108..117] mesangial)
            (NNS:[118..123] cells))
        (PP-LOC (IN:[124..126] at)
          (NP (DT:[127..130] the)
            (NML
              (NML (NN:[132..136] mRNA)
                (NML-1 (-NONE-:[136..136] *P*)))
              (CC:[137..140] and)
              (NML (NN:[141..147] enzyme)
                (NML-1 (NN:[148..153] level))))))))
    (.:[153..154] .)))

;sentence 2 Span:155..249
;Evidence for CYP1A1 and CYP1B1 expression and their  involvement in
;benzo[a]pyrene metabolism.
;[168..174]:cyp450:"CYP1A1"
;[179..185]:cyp450:"CYP1B1"
;[223..237]:substance:"benzo[a]pyrene"
(SENT
  (NP-HLN
    (NP (NN:[155..163] Evidence))
    (PP (IN:[164..167] for)
      (NP
        (NP
          (NP (NN:[168..174] CYP1A1)
            (NML-1 (-NONE-:[174..174] *P*)))
          (CC:[175..178] and)
          (NP (NN:[179..185] CYP1B1)
            (NML-1 (NN:[186..196] expression))))
        (CC:[197..200] and)
        (NP
          (NP (PRP$:[201..206] their) (NN:[208..219] involvement))
          (PP (IN:[220..222] in)
            (NP (NN:[223..237] benzo-LSB-a-RSB-pyrene)
                (NN:[238..248] metabolism))))))
    (.:[248..249] .)))

;section 3 Span:253..354
;Bowes RC 3rd, Parrish AR, Steinberg MA, Willett KL, Zhao W, Savas U, Jefcoate
; CR, Safe SH, Ramos KS.
(SEC
  (FRAG (NNP:[253..258] Bowes) (NNP:[259..261] RC) (CD:[262..265] 3rd)
        (,:[265..266] ,) (NNP:[267..274] Parrish) (NNP:[275..277] AR)
        (,:[277..278] ,) (NNP:[279..288] Steinberg) (NNP:[289..291] MA)
        (,:[291..292] ,) (NNP:[293..300] Willett) (NNP:[301..303] KL)
        (,:[303..304] ,) (NNP:[305..309] Zhao) (NNP:[310..311] W)
        (,:[311..312] ,) (NNP:[313..318] Savas) (NNP:[319..320] U)
        (,:[320..321] ,) (NNP:[322..330] Jefcoate) (NNP:[332..334] CR)
        (,:[334..335] ,) (NNP:[336..340] Safe) (NNP:[341..343] SH)
        (,:[343..344] ,) (NNP:[345..350] Ramos) (NNP:[351..353] KS)
        (.:[353..354] .)))

;section 4 Span:358..506
;Faculty of Toxicology, Department of Physiology and Pharmacology, College of 
;Veterinary Medicine, Texas A&M University, College Station 77843, USA.
(SEC
  (FRAG (NNP:[358..365] Faculty) (IN:[366..368] of) (NNP:[369..379] Toxicology)
        (,:[379..380] ,) (NNP:[381..391] Department) (IN:[392..394] of)
        (NNP:[395..405] Physiology) (CC:[406..409] and)
        (NNP:[410..422] Pharmacology) (,:[422..423] ,) (NNP:[424..431] College)
        (IN:[432..434] of) (NNP:[436..446] Veterinary) (NNP:[447..455] Medicine)
        (,:[455..456] ,) (NNP:[457..462] Texas) (NNP:[463..466] A&M)
        (NNP:[467..477] University) (,:[477..478] ,) (NNP:[479..486] College)
        (NNP:[487..494] Station) (NNP:[495..500] 77843) (,:[500..501] ,)
        (NNP:[502..505] USA) (.:[505..506] .)))

;sentence 5 Span:510..701
;Recent studies in this laboratory have shown that benzo[a]pyrene (BaP)
;modulates  growth factor-related gene expression and proliferation of renal
;glomerular  mesangial cells (GMCs) in vitro.
;[560..574]:substance:"benzo[a]pyrene"
;[576..579]:substance:"BaP"
;[592..605]:substance:"growth factor"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[510..516] Recent) (NNS:[517..524] studies))
      (PP-LOC (IN:[525..527] in)
        (NP (DT:[528..532] this) (NN:[533..543] laboratory))))
    (VP (VBP:[544..548] have)
      (VP (VBN:[549..554] shown)
        (SBAR (IN:[555..559] that)
          (S
            (NP-SBJ
              (NP (NN:[560..574] benzo-LSB-a-RSB-pyrene))
              (NP (-LRB-:[575..576] -LRB-) (NN:[576..579] BaP)
                  (-RRB-:[579..580] -RRB-)))
            (VP (VBZ:[581..590] modulates)
              (NP
                (NP
                  (ADJP
                    (NML (NN:[592..598] growth) (NN:[599..605] factor))
                    (HYPH:[605..606] -) (VBN:[606..613] related))
                  (NN:[614..618] gene) (NN:[619..629] expression))
                (CC:[630..633] and)
                (NP
                  (NP (NN:[634..647] proliferation))
                  (PP (IN:[648..650] of)
                    (NP (JJ:[651..656] renal)
                      (NML
                        (NML (JJ:[657..667] glomerular)
                             (JJ:[669..678] mesangial) (NNS:[679..684] cells))
                        (NML (-LRB-:[685..686] -LRB-) (NNS:[686..690] GMCs)
                             (-RRB-:[690..691] -RRB-)))))))
              (ADVP (FW:[692..694] in) (FW:[695..700] vitro)))))))
    (.:[700..701] .)))

;sentence 6 Span:702..1030
;Because many of the toxic and biochemical  effects of this polycyclic
;aromatic hydrocarbon are mediated through oxidative  metabolism, the present
;studies were conducted to examine the patterns of  cytochrome P450IA1
;(CYP1A1) and P4501B1 (CYP1B1) inducibility in mesangial cells  and the
;molecular consequences of this response.
;[761..792]:substance:"polycyclic aromatic hydrocarbon"
;[900..918]:cyp450:"cytochrome P450IA1"
;[900..910]...[932..939]:cyp450:"cytochrome"..."P4501B1"
;[920..926]:cyp450:"CYP1A1"
;[941..947]:cyp450:"CYP1B1"
(SENT
  (S
    (SBAR-ADV (IN:[702..709] Because)
      (S
        (NP-SBJ-4
          (NP (NN:[710..714] many))
          (PP (IN:[715..717] of)
            (NP
              (NP (DT:[718..721] the)
                (NML
                  (NML (JJ:[722..727] toxic)
                    (NML-3 (-NONE-:[727..727] *P*)))
                  (CC:[728..731] and)
                  (NML (JJ:[732..743] biochemical)
                    (NML-3 (NNS:[745..752] effects)))))
              (PP (IN:[753..755] of)
                (NP (DT:[756..760] this)
                   (JJ:[761..771] polycyclic) (JJ:[772..780] aromatic)
                   (NN:[781..792] hydrocarbon))))))
        (VP (VBP:[793..796] are)
          (VP (VBN:[797..805] mediated)
            (NP-4 (-NONE-:[805..805] *))
            (PP-MNR (IN:[806..813] through)
              (NP (JJ:[814..823] oxidative) (NN:[825..835] metabolism)))))))
    (,:[835..836] ,)
    (NP-SBJ-2 (DT:[837..840] the) (JJ:[841..848] present)
              (NNS:[849..856] studies))
    (VP (VBD:[857..861] were)
      (VP (VBN:[862..871] conducted)
        (NP-2 (-NONE-:[871..871] *))
        (S-PRP
          (NP-SBJ (-NONE-:[871..871] *))
          (VP (TO:[872..874] to)
            (VP (VB:[875..882] examine)
              (NP
                (NP
                  (NP (DT:[883..886] the) (NNS:[887..895] patterns))
                  (PP (IN:[896..898] of)
                    (NP
                      (NP
                        (NML
                          (NML
                            (NML
                              (NML-1 (NN:[900..910] cytochrome))
                              (NN:[911..918] P450IA1))
                            (NML (-LRB-:[919..920] -LRB-) (NN:[920..926] CYP1A1)
                                 (-RRB-:[926..927] -RRB-)))
                          (CC:[928..931] and)
                          (NML
                            (NML
                              (NML-1 (-NONE-:[931..931] *P*))
                              (NN:[932..939] P4501B1))
                            (NML (-LRB-:[940..941] -LRB-) (NN:[941..947] CYP1B1)
                                 (-RRB-:[947..948] -RRB-))))
                        (NN:[949..961] inducibility))
                      (PP-LOC (IN:[962..964] in)
                        (NP (JJ:[965..974] mesangial) (NNS:[975..980] cells))))))
                (CC:[982..985] and)
                (NP
                  (NP (DT:[986..989] the) (JJ:[990..999] molecular)
                      (NNS:[1000..1012] consequences))
                  (PP (IN:[1013..1015] of)
                    (NP (DT:[1016..1020] this) (NN:[1021..1029] response))))))))))
    (.:[1029..1030] .)))

;sentence 7 Span:1031..1235
;Exposure of cultured GMCs to  BaP (30 microM) or
;2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, 10 nM) for 24 hr  induced CYP1A1
;mRNA levels, a response abolished by cotreatment with 10 microM 
;cycloheximide.
;[1061..1064]:substance:"BaP"
;[1066..1068]:quantitative-value:"30"
;[1069..1075]:quantitative-units:"microM"
;[1080..1115]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
;[1117..1121]:substance:"TCDD"
;[1123..1125]:quantitative-value:"10"
;[1126..1128]:quantitative-units:"nM"
;[1134..1136]:quantitative-value:"24"
;[1137..1139]:quantitative-units:"hr"
;[1149..1160]:substance:"CYP1A1 mRNA"
;[1210..1212]:quantitative-value:"10"
;[1213..1219]:quantitative-units:"microM"
;[1221..1234]:substance:"cycloheximide"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1031..1039] Exposure))
      (PP (IN:[1040..1042] of)
        (NP (JJ:[1043..1051] cultured) (NNS:[1052..1056] GMCs)))
      (PP (TO:[1057..1059] to)
        (NP
          (NP
            (NP (NN:[1061..1064] BaP))
            (PRN (-LRB-:[1065..1066] -LRB-)
              (NP (CD:[1066..1068] 30) (NN:[1069..1075] microM))
              (-RRB-:[1075..1076] -RRB-)))
          (CC:[1077..1079] or)
          (NP
            (NP
              (NP (NN:[1080..1115] 2,3,7,8-tetrachlorodibenzo-p-dioxin))
              (NP (-LRB-:[1116..1117] -LRB-) (NN:[1117..1121] TCDD)))
            (PRN (,:[1121..1122] ,)
              (NP (CD:[1123..1125] 10) (NN:[1126..1128] nM))
              (-RRB-:[1128..1129] -RRB-)))))
      (PP-TMP (IN:[1130..1133] for)
        (NP (CD:[1134..1136] 24) (NN:[1137..1139] hr))))
    (VP (VBD:[1141..1148] induced)
      (NP
         (NN:[1149..1155] CYP1A1) (NN:[1156..1160] mRNA)
        (NNS:[1161..1167] levels))
      (,:[1167..1168] ,)
      (NP-ADV
        (NP (DT:[1169..1170] a) (NN:[1171..1179] response))
        (VP (VBN:[1180..1189] abolished)
          (NP (-NONE-:[1189..1189] *))
          (PP (IN:[1190..1192] by)
            (NP-LGS
              (NP (NN:[1193..1204] cotreatment))
              (PP (IN:[1205..1209] with)
                (NP (CD:[1210..1212] 10) (NN:[1213..1219] microM)
                    (NN:[1221..1234] cycloheximide))))))))
    (.:[1234..1235] .)))

;sentence 8 Span:1236..1491
;The pattern of hydrocarbon inducibility was atypical in that BaP  was a more
;effective inducer of CYP1A1 gene expression than TCDD, and both  hydrocarbons
;induced aryl hydrocarbon hydroxylase (AHH) activity, but not 
;ethoxyresorufin-O-deethylase activity.
;[1251..1262]:substance:"hydrocarbon"
;[1297..1300]:substance:"BaP"
;[1323..1330]:substance:"inducer"
;[1362..1366]:substance:"TCDD"
;[1378..1390]:substance:"hydrocarbons"
;[1399..1427]:cyp450:"aryl hydrocarbon hydroxylase"
;[1429..1432]:cyp450:"AHH"
;[1453..1481]:cyp450:"ethoxyresorufin-O-deethylase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1236..1239] The) (NN:[1240..1247] pattern))
      (PP (IN:[1248..1250] of)
        (NP (NN:[1251..1262] hydrocarbon) (NN:[1263..1275] inducibility))))
    (VP (VBD:[1276..1279] was)
      (ADJP-PRD (JJ:[1280..1288] atypical))
      (SBAR (IN:[1289..1291] in) (IN:[1292..1296] that)
        (S
          (S
            (NP-SBJ (NN:[1297..1300] BaP))
            (VP (VBD:[1302..1305] was)
              (NP-PRD
                (NP (DT:[1306..1307] a)
                  (ADJP (RBR:[1308..1312] more) (JJ:[1313..1322] effective))
                  (NN:[1323..1330] inducer))
                (PP (IN:[1331..1333] of)
                  (NP (NN:[1334..1340] CYP1A1) (NN:[1341..1345] gene)
                      (NN:[1346..1356] expression)))
                (PP (IN:[1357..1361] than)
                  (NP (NN:[1362..1366] TCDD))))))
          (,:[1366..1367] ,) (CC:[1368..1371] and)
          (S
            (NP-SBJ (DT:[1372..1376] both) (NNS:[1378..1390] hydrocarbons))
            (VP (VBD:[1391..1398] induced)
              (NP
                (NP
                  (NML
                    (NML (NN:[1399..1403] aryl) (NN:[1404..1415] hydrocarbon)
                         (NN:[1416..1427] hydroxylase))
                    (NML (-LRB-:[1428..1429] -LRB-) (NN:[1429..1432] AHH)
                         (-RRB-:[1432..1433] -RRB-)))
                  (NN:[1434..1442] activity))
                (,:[1442..1443] ,)
                (CONJP (CC:[1444..1447] but) (RB:[1448..1451] not))
                (NP (NN:[1453..1481] ethoxyresorufin-O-deethylase)
                    (NN:[1482..1490] activity))))))))
    (.:[1490..1491] .)))

;sentence 9 Span:1492..1658
;Cotreatment with alpha-naphthoflavone  (alpha NF, 1 microM) or ellipticine
;(ELLIP, 0.1 nM) only partially inhibited the  induction of AHH activity by
;BaP (30 microM).
;[1509..1529]:substance:"alpha-naphthoflavone"
;[1532..1540]:substance:"alpha NF"
;[1542..1543]:quantitative-value:"1"
;[1544..1550]:quantitative-units:"microM"
;[1555..1566]:substance:"ellipticine"
;[1568..1573]:substance:"ELLIP"
;[1575..1578]:quantitative-value:"0.1"
;[1579..1581]:quantitative-units:"nM"
;[1626..1629]:cyp450:"AHH"
;[1642..1645]:substance:"BaP"
;[1647..1649]:quantitative-value:"30"
;[1650..1656]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1492..1503] Cotreatment))
      (PP (IN:[1504..1508] with)
        (NP
          (NP
            (NP (NN:[1509..1529] alpha-naphthoflavone))
            (NP (-LRB-:[1531..1532] -LRB-)
               (SYM:[1532..1537] alpha) (NN:[1538..1540] NF))
            (PRN (,:[1540..1541] ,)
              (NP (CD:[1542..1543] 1) (NN:[1544..1550] microM))
              (-RRB-:[1550..1551] -RRB-)))
          (CC:[1552..1554] or)
          (NP
            (NP (NN:[1555..1566] ellipticine))
            (NP (-LRB-:[1567..1568] -LRB-) (NN:[1568..1573] ELLIP))
            (PRN (,:[1573..1574] ,)
              (NP (CD:[1575..1578] 0.1) (NN:[1579..1581] nM))
              (-RRB-:[1581..1582] -RRB-))))))
    (VP
      (ADVP (RB:[1583..1587] only) (RB:[1588..1597] partially))
      (VBD:[1598..1607] inhibited)
      (NP
        (NP (DT:[1608..1611] the) (NN:[1613..1622] induction))
        (PP (IN:[1623..1625] of)
          (NP
            (NP (NN:[1626..1629] AHH) (NN:[1630..1638] activity))
            (PP (IN:[1639..1641] by)
              (NP (NN:[1642..1645] BaP)
                (PRN (-LRB-:[1646..1647] -LRB-) (CD:[1647..1649] 30)
                     (NN:[1650..1656] microM) (-RRB-:[1656..1657] -RRB-))))))))
    (.:[1657..1658] .)))

;sentence 10 Span:1659..1792
;BaP and TCDD also induced  expression of the CYP1B1 protein and the pattern
;of induction was comparable to  that observed for CYP1A1.
;[1659..1662]:substance:"BaP"
;[1667..1671]:substance:"TCDD"
;[1704..1718]:cyp450:"CYP1B1 protein"
;[1785..1791]:cyp450:"CYP1A1"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1659..1662] BaP) (CC:[1663..1666] and) (NN:[1667..1671] TCDD))
      (VP
        (ADVP (RB:[1672..1676] also))
        (VBD:[1677..1684] induced)
        (NP
          (NP (NN:[1686..1696] expression))
          (PP (IN:[1697..1699] of)
            (NP (DT:[1700..1703] the)
               (NN:[1704..1710] CYP1B1) (NN:[1711..1718] protein))))))
    (CC:[1719..1722] and)
    (S
      (NP-SBJ
        (NP (DT:[1723..1726] the) (NN:[1727..1734] pattern))
        (PP (IN:[1735..1737] of)
          (NP (NN:[1738..1747] induction))))
      (VP (VBD:[1748..1751] was)
        (ADJP-PRD (JJ:[1752..1762] comparable)
          (PP (TO:[1763..1765] to)
            (NP
              (NP (DT:[1767..1771] that))
              (VP (VBN:[1772..1780] observed)
                (NP (-NONE-:[1780..1780] *))
                (PP (IN:[1781..1784] for)
                  (NP (NN:[1785..1791] CYP1A1)))))))))
    (.:[1791..1792] .)))

;sentence 11 Span:1793..1993
;Treatment of GMCs with 30 microM BaP was associated  with the formation of
;eight DNA adducts, and their occurrence could be inhibited  by pretreatment
;with alpha NF (1 microM), but not ELLIP (0.1 nM).
;[1816..1818]:quantitative-value:"30"
;[1819..1825]:quantitative-units:"microM"
;[1826..1829]:substance:"BaP"
;[1874..1885]:substance:"DNA adducts"
;[1949..1957]:substance:"alpha NF"
;[1959..1960]:quantitative-value:"1"
;[1961..1967]:quantitative-units:"microM"
;[1978..1983]:substance:"ELLIP"
;[1985..1988]:quantitative-value:"0.1"
;[1989..1991]:quantitative-units:"nM"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (NN:[1793..1802] Treatment))
        (NP (IN:[1803..1805] of)
          (NP (NNS:[1806..1810] GMCs)))
        (PP (IN:[1811..1815] with)
          (NP (CD:[1816..1818] 30) (NN:[1819..1825] microM)
              (NN:[1826..1829] BaP))))
      (VP (VBD:[1830..1833] was)
        (VP (VBN:[1834..1844] associated)
          (NP-2 (-NONE-:[1844..1844] *))
          (PP-CLR (IN:[1846..1850] with)
            (NP
              (NP (DT:[1851..1854] the) (NN:[1855..1864] formation))
              (PP (IN:[1865..1867] of)
                (NP (CD:[1868..1873] eight)
                   (NN:[1874..1877] DNA) (NNS:[1878..1885] adducts))))))))
    (,:[1885..1886] ,) (CC:[1887..1890] and)
    (S
      (NP-SBJ-1 (PRP$:[1891..1896] their) (NN:[1897..1907] occurrence))
      (VP (MD:[1908..1913] could)
        (VP (VB:[1914..1916] be)
          (VP (VBN:[1917..1926] inhibited)
            (NP-1 (-NONE-:[1926..1926] *))
            (PP (IN:[1928..1930] by)
              (NP-LGS
                (NP (NN:[1931..1943] pretreatment))
                (PP (IN:[1944..1948] with)
                  (NP
                    (NP
                       (SYM:[1949..1954] alpha) (NN:[1955..1957] NF)
                      (PRN (-LRB-:[1958..1959] -LRB-)
                        (NP (CD:[1959..1960] 1) (NN:[1961..1967] microM))
                        (-RRB-:[1967..1968] -RRB-)))
                    (,:[1968..1969] ,)
                    (CONJP (CC:[1970..1973] but) (RB:[1974..1977] not))
                    (NP (NN:[1978..1983] ELLIP)
                      (PRN (-LRB-:[1984..1985] -LRB-)
                        (NP (CD:[1985..1988] 0.1) (NN:[1989..1991] nM))
                        (-RRB-:[1991..1992] -RRB-)))))))))))
    (.:[1992..1993] .)))

;sentence 12 Span:1994..2211
;These results  demonstrate that CYP1A1 and CYP1B1-related activities are
;induced in GMCs by BaP  and TCDD and this induction is associated with
;metabolism of BaP to reactive  intermediates that bind covalently to DNA.
;[2026..2032]:cyp450:"CYP1A1"
;[2037..2043]:cyp450:"CYP1B1"
;[2086..2089]:substance:"BaP"
;[2095..2099]:substance:"TCDD"
;[2152..2155]:substance:"BaP"
;[2169..2182]:substance:"intermediates"
;[2207..2210]:substance:"DNA"
(SENT
  (S
    (NP-SBJ (DT:[1994..1999] These) (NNS:[2000..2007] results))
    (VP (VBP:[2009..2020] demonstrate)
      (SBAR (IN:[2021..2025] that)
        (S
          (S
            (NP-SBJ-4
              (ADJP
                (ADJP (NN:[2026..2032] CYP1A1)
                  (ADJP-3 (-NONE-:[2032..2032] *P*)))
                (CC:[2033..2036] and)
                (ADJP (NN:[2037..2043] CYP1B1)
                  (ADJP-3 (HYPH:[2043..2044] -) (VBN:[2044..2051] related))))
              (NNS:[2052..2062] activities))
            (VP (VBP:[2063..2066] are)
              (VP (VBN:[2067..2074] induced)
                (NP-4 (-NONE-:[2074..2074] *))
                (PP-CLR (IN:[2075..2077] in)
                  (NP (NNS:[2078..2082] GMCs)))
                (PP (IN:[2083..2085] by)
                  (NP-LGS (NN:[2086..2089] BaP) (CC:[2091..2094] and)
                          (NN:[2095..2099] TCDD))))))
          (CC:[2100..2103] and)
          (S
            (NP-SBJ-2 (DT:[2104..2108] this) (NN:[2109..2118] induction))
            (VP (VBZ:[2119..2121] is)
              (VP (VBN:[2122..2132] associated)
                (NP-2 (-NONE-:[2132..2132] *))
                (PP-CLR (IN:[2133..2137] with)
                  (NP
                    (NP (NN:[2138..2148] metabolism))
                    (PP (IN:[2149..2151] of)
                      (NP (NN:[2152..2155] BaP)))
                    (PP (TO:[2156..2158] to)
                      (NP
                        (NP (JJ:[2159..2167] reactive)
                            (NNS:[2169..2182] intermediates))
                        (SBAR
                          (WHNP-1 (WDT:[2183..2187] that))
                          (S
                            (NP-SBJ-1 (-NONE-:[2187..2187] *T*))
                            (VP (VBP:[2188..2192] bind)
                              (ADVP (RB:[2193..2203] covalently))
                              (PP-CLR (TO:[2204..2206] to)
                                (NP (NN:[2207..2210] DNA))))))))))))))))
    (.:[2210..2211] .)))

;section 13 Span:2215..2259
;PMID: 8759031 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2215..2219] PMID) (::[2219..2220] :) (CD:[2221..2228] 8759031)
        (NN:[2229..2230] -LSB-) (NNP:[2230..2236] PubMed) (::[2237..2238] -)
        (NN:[2239..2246] indexed) (IN:[2247..2250] for)
        (NNP:[2251..2259] MEDLINE-RSB-)))
